Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
Henan Cancer Hospital
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
78High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06618391CT.gov Local Injection and Systemic Therapy in the Treatment of NSCLC. | — | Not Yet Recruiting | — | — | — |
NCT06617936CT.gov Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer. | — | Recruiting | — | — | — |
NCT05529355CT.gov Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT05448781CT.gov Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC | — | Unknown | — | — | — |
NCT04942301CT.gov PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy | — | Unknown | — | — | — |
NCT04094909CT.gov Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC | — | Unknown | — | — | — |
NCT04063449CT.gov Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLC | — | Unknown | — | — | — |
NCT03461185CT.gov Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT03123445CT.gov Endostar First-line Treatment of Advanced NSCLC | — | Unknown | — | — | — |
NCT03614065CT.gov Endostar Combine With Radiotherapy in Brain Metastasis of NSCLC | — | Unknown | — | — | — |
Show 17 more trialsShow fewer
NCT02579564CT.gov Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients | — | Unknown | — | — | — |
NCT02652234CT.gov Study of Endostar Subcutaneous Injection in NSCLC | — | Unknown | — | — | — |
NCT02513355CT.gov Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research | — | Unknown | — | — | — |
NCT02001168CT.gov Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB | — | Unknown | — | — | — |
NCT01531790CT.gov A Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced Non Small Cell Lung Cancer Patients | — | Completed | — | — | — |
NCT01549093CT.gov Endostar Continued Pumping Into Vein Combining With Gemcitabine-Carboplatin to Treat Non-Small Cell Lung Cancer (NSCLC) | — | Unknown | — | — | — |
NCT01669707CT.gov Endostar Durative Transfusion Combining With Gemcitabine-Cisplatin to Treat Non-Small Cell Lung Cancer (NSCLC) | — | Unknown | — | — | — |
NCT01347424CT.gov Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement Ultrasonography | — | Unknown | — | — | — |
NCT01211002CT.gov Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC) | — | Unknown | — | — | — |
NCT02497118CT.gov Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC | — | Completed | — | — | — |
NCT01158144CT.gov Concurrent Endostar, Paclitaxel/Carboplatin and Radiotherapy for Locally Advanced Non-small Cell Lung (RT0902) | — | Unknown | — | — | — |
NCT01028729CT.gov A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC) | — | Unknown | — | — | — |
NCT01192230CT.gov Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients | — | Unknown | — | — | — |
NCT01218594CT.gov Curative Effect Study of Endostatin Combined With Chemoradiotherapy to Non-small-cell Lung Cancer | — | Unknown | — | — | — |
NCT01687439CT.gov Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00813332CT.gov Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC) | — | Unknown | — | — | — |
NCT00708812CT.gov Paclitaxel Plus Carboplatin With or Without Endostar in Patients With Advanced Non-small Cell Lung Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Endostatin (this asset) | Henan Cancer Hospital | Approved | BB · 70 |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Veliparib | AbbVie | P3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Zoledronate | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P4 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Avitinib | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | P3 | BBB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Endostatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Neoplasm | — | P3 | B · 63 |
| Lung Cancer | — | P4 | B · 60 |
| Lung Neoplasm | — | P3 | B · 59 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Endostatin in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/endostatin-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →